Goldman Sachs analyst Nathan Rich double upgraded Dentsply Sirona to Buy from Sell and raised his price target for the shares to $44 from $37. Following nearly 50% underperformance year-to-date versus the S&P 500 Index, the analyst now believes consensus estimates are achievable and that Dentsply's valuation is attractive relative to Medtech peers. Further, he sees see potential value creation from additional cost savings. Dentsply at current levels offers an "attractive n entry point to own an interesting turnaround story," Rich tells investors in a research note.